FIELD MEDICAL ANNOUNCES FIRST-IN-HUMAN DATA FOR FOCAL PFA IN SCAR-RELATED VT AT HEART RHYTHM 2025 USA - English APAC - English USA - English
The Californer/10311600

Eight presentations, including late ~ Field Medical Inc., a leading company in cardiac pulsed field ablation (PFA) technology, has announced that its FieldForce™ Ablation System will be prominently featured in eight scientific presentations at the 46th annual Heart Rhythm Society (HRS) meeting. The meeting, which will take place from April 24-27 in San Diego, California, is expected to draw over 9,000 attendees and 2,000 expert faculty.

The FieldForce™ Ablation System is a catheter designed to reach the epicardium from the endocardium and enable focal pulsed field ablation for full-thickness, transmural lesions. This innovative system will be showcased in various presentations including live case demonstrations, poster sessions, and a flagship satellite symposium.

One of the highlights of the HRS meeting will be the late-breaking VCAS trial on Sunday, April 27. This trial will unveil acute results from the first-in-human evaluation of focal PFA for scar-related ventricular tachycardia (VT). Scar VT is a challenging arrhythmia characterized by dense fibrotic substrates and high recurrence rates.

More on The Californer

• Can This Simple Test Predict How Long You'll Live?
• AI Performs Virtual Tissue Staining at Super-Resolution
• Online Distribution of the Summer 2025 Diamond Certified Directory Update Begins
• California: Governor Newsom proclaims Immigrant Heritage Month 2025
• California: Department of Defense agrees: it's time for Trump's militarization of Los Angeles to end

Field Medical's CEO and Founder, Dr. Steven Mickelsen, expressed his excitement about the potential of FieldForce™ Ablation System to revolutionize PFA technology. "For decades, VT has been a difficult condition for even the most skilled electrophysiologists due to its complex scar substrate," said Dr. Mickelsen. "With FieldForce™ Ablation System, we are not just making incremental improvements – we are redefining what is possible. This new focal PFA system has the potential to address areas of greatest unmet need in electrophysiology."

Field Medical's participation in HRS 2025 reflects their commitment to advancing science and improving outcomes in VT and PFA innovation. The company's scientific presentations and events at HRS 2025 include a presentation at the Innovation Spotlight by Stanford Biodesign, a New Arrhythmia Technologies Retreat on April 23 featuring Dr. Steven Mickelsen, and a Late-Breaking Clinical Trial on April 27 presented by Dr. Vivek Reddy.

More on The Californer

• Long Beach: City Launches Internet Service Enrollment Line
• Von Rock Law Founder Deidre Von Rock Named Super Lawyer for 2025
• California: Governor Newsom extends emergency short-term housing protections in Los Angeles
• Von Rock Law Named SFGate's Best Probate and Estate Attorney in 2025
• Long Beach to Conduct Annual Summer Recess for City Council Meetings During July

The FieldForce™ Ablation System will also be featured in live case demonstrations at the PFA Live Case Summit on April 24, where Drs. Vivek Reddy and Petr Neužil will showcase its potential in treating VT and pulmonary vein isolation (PVI). Additionally, the system will be highlighted in poster presentations at the Abstract Pavilion in the Exhibit Hall on April 25-26.

A satellite symposium titled "PFA in the Ventricle: The Future of Ablation" will also take place on April 25, featuring a panel of renowned experts including Drs. Pierre Jais, Jacob Koruth, Damijan Miklavčič, Steven Mickelsen, Kars Neven, Andrea Natale, Vivek Reddy, and Roderick Tung.

Field Medical's participation in HRS 2025 demonstrates their dedication to pushing the boundaries of PFA technology and improving outcomes for patients with VT. With their FieldForce™ Ablation System at the forefront of these presentations and events, it is clear that Field Medical is committed to shaping the future of cardiac ablation.

---

Show All News | Report Violation